Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xia, Chuan | - |
dc.contributor.author | Seo, Young-Jin | - |
dc.contributor.author | Studstill, Caleb J. | - |
dc.contributor.author | Vijayan, Madhuvanthi | - |
dc.contributor.author | Wolf, Jennifer J. | - |
dc.contributor.author | Hahm, Bumsuk | - |
dc.date.available | 2019-01-22T12:34:59Z | - |
dc.date.issued | 2018-10 | - |
dc.identifier.issn | 0166-3542 | - |
dc.identifier.issn | 1872-9096 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/724 | - |
dc.description.abstract | Influenza continues to pose a threat to public health by causing illness and mortality in humans. Discovering host factors that regulate influenza virus propagation is vital for the development of novel drugs. We have previously reported that sphingosine kinase (SphK) 1 promotes influenza A virus (IAV) replication in vitro. Here we demonstrate that the other isoform of SphK, SphK2 promotes the replication of influenza A virus (IAV) in cultured cells, and temporary inhibition of SphK1 or SphK2 enhances the host defense against influenza in mice. IAV infection led to an increased expression and phosphorylation of SphK2 in host cells. Furthermore, pharmacologic inhibition or siRNA-based knockdown of SphK2 attenuated IAV replication in vitro. Notably, oral administration of an SphK2-specific inhibitor substantially improved the viability of mice following IAV infection. In addition, the local instillation of an SphK1-specific inhibitor or an inhibitor that globally blocks SphK1 and SphK2 provided protection to IAV-infected mice. Collectively, our results indicate that both SphK1 and SphK2 function as proviral factors during IAV infection in vivo. Therefore, SphK1 and SphK2 represent potential host targets for therapeutics against influenza. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.antiviral.2018.08.010 | - |
dc.identifier.bibliographicCitation | ANTIVIRAL RESEARCH, v.158, pp 171 - 177 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000446144000019 | - |
dc.identifier.scopusid | 2-s2.0-85052083793 | - |
dc.citation.endPage | 177 | - |
dc.citation.startPage | 171 | - |
dc.citation.title | ANTIVIRAL RESEARCH | - |
dc.citation.volume | 158 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Influenza virus | - |
dc.subject.keywordAuthor | Sphingosine kinase 2 | - |
dc.subject.keywordAuthor | Sphingosine kinase 1 | - |
dc.subject.keywordPlus | MULTIPLE-SCLEROSIS | - |
dc.subject.keywordPlus | SPHINGOLIPID METABOLISM | - |
dc.subject.keywordPlus | THERAPEUTIC TARGETS | - |
dc.subject.keywordPlus | FINGOLIMOD FTY720 | - |
dc.subject.keywordPlus | VIRAL REPLICATION | - |
dc.subject.keywordPlus | PROTEIN-KINASE | - |
dc.subject.keywordPlus | SPHINGOSINE-1-PHOSPHATE | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | 1-PHOSPHATE | - |
dc.subject.keywordPlus | MODULATION | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.